<DOC>
	<DOCNO>NCT01919619</DOCNO>
	<brief_summary>The goal clinical research study study safety REVLIMID® ( lenalidomide ) give YERVOY® ( ipilimumab ) stem cell transplant . Researchers also want find lenalidomide give ipilimumab may help control leukemia lymphoma .</brief_summary>
	<brief_title>Lenalidomide Ipilimumab Post Allo Auto Stem Cell Transplantation ( SCT )</brief_title>
	<detailed_description>Study Groups : If agree take part study , assign dose level lenalidomide base join study whether intolerable side effect see previous participant . Two ( 2 ) dose level lenalidomide test . The first group 3 participant receive high dose level lenalidomide . If intolerable side effect see first 3 participant , remain participant receive low dose lenalidomide . All participant receive dose ipilimumab . Study Drug Administration Lenalidomide On Days 1-21 Cycles 1 , 3 , 5 , 7 , take lenalidomide mouth day . You take lenalidomide time day . You swallow lenalidomide capsule whole water . Do open , crush , break lenalidomide capsule . If touch broken lenalidomide capsule , wash area body soap water . If miss dose lenalidomide , le 12 hour since regular dose time , take soon remember . If 12 hour , skip miss dose . Do take 2 dos time . If take much lenalidomide , call healthcare provider right away . If vomit dose , take another dose . Ipilimumab : About 1 3 day last dose lenalidomide Cycles 1 , 3 , 5 , 7 , receive ipilimumab vein 90 minute . About 4 week ipilimumab infusion , start take lenalidomide describe . You give study drug diary . You use diary write time take dose lenalidomide . You need bring study drug diary every study visit study staff review . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . Study Visits : Before Cycles 1 , 3 , 5 , 7 : - You physical exam . - Blood ( 2 tablespoon ) draw routine test check kidney liver function . On Day 14 Cycles 1 , 3 , 5 , 7 , blood ( 1 tablespoon ) drawn routine test . Before Cycles 2 , 4 , 6 , 8 : - You physical exam . - Blood ( 2 tablespoon ) draw routine test check adrenal gland , pituitary gland , kidney , liver , thyroid function . - You eye exam check side effect , doctor think need . - If receive allogeneic stem cell transplant , check sign graft-versus-host disease ( GVHD ) . You tell GVHD time prepared transplant . GVHD may cause skin rash , diarrhea , abdominal cramping , and/or damage liver , lung , eye , mouth , skin , joint , gastrointestinal tract , and/or muscle . It may result jaundice ( yellow skin and/or eye ) . Pregnancy Tests : If become pregnant , pregnancy counsel test long take lenalidomide . Blood ( ½ teaspoon ) urine collect pregnancy test follow time : - around 10-14 day first dose lenalidomide . - 24 hour first dose lenalidomide Cycles 1 , 3 , 5 , 7 . - one ( 1 ) time week first 4 week take lenalidomide . - one ( 1 ) time every 4 week rest treatment regular menstrual cycle cycle within 24 month , every 2 week irregular menstrual cycle . If period irregular , blood ( ½ teaspoon ) drawn pregnancy test 2 week first dose lenalidomide 28 day last dose lenalidomide . Length Study : You may continue take study drug 8 cycle . You may take study drug early disease get bad , intolerable side effect , unable follow study direction , doctor think best interest , study stop . Your participation study follow-up visit . Follow-up Visits : After last dose ipilimumab , 1 , 3 , 6 , 12 , 24 , 36 month later : - You physical exam . - Blood ( 2 tablespoon ) draw routine test check adrenal gland , pituitary gland , kidney , liver function . - If receive allogeneic stem cell transplant , check sign GVHD . - You bone marrow aspiration biopsy check status disease , doctor think need . To collect bone marrow biopsy/aspirate , area hip chest bone numb anesthetic , small amount bone bone marrow withdrawn large needle . - You positron emission tomography - compute tomography ( PET-CT ) scan and/or CT scan , doctor think need . A PET-CT CT scan take small amount radioactive glucose ( sugar ) inject vein find cancer cell body . The tests/procedures may perform often , doctor think need . If become pregnant , blood ( ½ teaspoon ) drawn pregnancy test follow schedule : - stop lenalidomide therapy 28 day later ( regular menstrual cycle ) - stop lenalidomide therapy 14 28 day later ( irregular menstrual cycle ) This investigational study . Ipilimumab FDA approve commercially available treatment melanoma . Lenalidomide FDA approve commercially available treatment myeloma . The use ipilimumab combination lenalidomide stem cell transplant leukemia lymphoma consider investigational use research purpose . Up 30 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age &gt; /= 18 year &lt; /= 80 year . 2 . Hematologic lymphoid malignancy . 3 . Autologous patient include anytime within 6 month posttransplant , sign progression meet one follow criterion : i. Mantle cell lymphoma . ii . Nongerminal center Bcell like diffuse large Bcell lymphoma ( GCB DLBCL ) . iii . Doublehit lymphoma . iv . Triplehit lymphoma . v. Bcell lymphomas receive three line therapy . vi . Patients CR transplantation . vii . Hodgkin 's lymphoma . 4 . Allogeneic patient : . Patients engraft donor cell ( i.e. , &gt; 20 % donor Tcell PB/PCR ) ; , ii . Patients NOT CR allogeneic transplant , tacrolimus and/or mycophenolate mofetil least 3 4 week sign GVHD ; , iii . Patients evidence relapse transplant tacrolimus and/or mycophenolate mofetil immunosuppressant GVHD 3 4 week sign GVHD ( Prednisone dose &lt; /= 10 mg permit state previously ) . 5 . No active infection . 6 . ANC &gt; /= 1.5 x 10^9/L ; platelet &gt; 75 x 10^9/L . 7 . Able adhere study visit schedule protocol requirement . 8 . Performance status : ECOG 2 less Karnofsky least 60 . 9 . Cardiac EF &gt; /= 45 % 2DECHO within 3 month study entry ( within 1 month receive chemotherapy within past 3 month ) . 10 . FEV1 , FVC DLCO &gt; /= 40 % within 3 month study entry ( within 1 month receive chemotherapy within past 3 month ) . 11 . Serum creatinine &lt; /= 1.6 mg/dL creatinine clearance &gt; /= 30 ml/min . Creatinine clearance calculate use CockcroftGault equation : Use actual body weight less equal ideal body weight . Use ideal body weight patient great ideal body weight , less equal 50 % ideal body weight . Use adjust body weight patient great 50 % ideal body weight . 12 . Liver function test ( unless relate Gilbert 's disease medication ) ( 1 ) SGPT , SGOT le 2x upper limit normal range . ( 2 ) Direct Bilirubin &lt; 1.6 13 . Patient legally authorize representative able sign inform consent . 14 . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior study entry . 1 . Immunotherapy chemotherapy approve investigational anticancer therapeutic within 4 week first dose . 2 . Patients alemtuzumab within 6 week prior consent . 3 . Active congestive heart failure ( NYHA Class III IV ) , symptomatic ischemia conduction abnormality uncontrolled conventional intervention . Myocardial infarction within 6 month study entry . 4 . Deep vein thrombosis pulmonary embolism within 3 month study entry . 5 . Pregnant breastfeeding female . ( Lactating female must agree breastfeed take lenalidomide ) . 6 . Acute active infection require intravenous antibiotic , antiviral ( except antiviral direct hepatitis B ) , antifungal agent within 14 day first dose . 7 . Known HIV seropositive , hepatitis C infection , and/or hepatitis B ( except patient hepatitis B Sag core antibody receive respond antiviral therapy direct hepatitis B : patient allow ) . 8 . Patients known malignancy within past three year except : . Adequately treat basal squamous cell skin cancer . ii . Carcinoma situ cervix . iii . Prostate cancer Gleason score &lt; 6 stable PSA past three month . iv . Breast cancer situ full surgical resection . 9 . Significant neuropathy ( grade 3 4 grade 2 pain ) . 10 . Known hypersensitivity thalidomide , lenalidomide ipilimumab . 11 . Active lifethreatening autoimmune disease . 12 . Active GVHD recent GVHD still &gt; 10 mg prednisone ( equivalent ) . 13 . Prior autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Allogeneic stem cell transplant</keyword>
	<keyword>Autologous stem cell transplant</keyword>
	<keyword>SCT</keyword>
	<keyword>Lenalidomide CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Yervoy</keyword>
	<keyword>BMS-734016</keyword>
	<keyword>MDX010</keyword>
</DOC>